These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21479595)

  • 1. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C).
    Visser ME; Kropman E; Kranendonk ME; Koppen A; Hamers N; Stroes ES; Kalkhoven E; Monajemi H
    Diabetologia; 2011 Jul; 54(7):1639-44. PubMed ID: 21479595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.
    Akinci B; Onay H; Demir T; Savas-Erdeve Ş; Gen R; Simsir IY; Keskin FE; Erturk MS; Uzum AK; Yaylali GF; Ozdemir NK; Atik T; Ozen S; Yurekli BS; Apaydin T; Altay C; Akinci G; Demir L; Comlekci A; Secil M; Oral EA
    Metabolism; 2017 Jul; 72():109-119. PubMed ID: 28641778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation.
    Iizaka T; Kodama E; Mikura K; Iida T; Imai H; Hashizume M; Kigawa Y; Sugisawa C; Tadokoro R; Endo K; Otsuka F; Isoda M; Ebihara K; Ishibashi S; Nagasaka S
    Endocr J; 2023 Jan; 70(1):69-76. PubMed ID: 36171144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
    Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
    Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
    J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy.
    Padova G; Prudente S; Vinciguerra F; Sudano D; Baratta R; Bellacchio E; Trischitta V; Vallone A; Sciacca L; Frittitta L
    Acta Diabetol; 2020 May; 57(5):589-596. PubMed ID: 31863320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.
    Demir T; Onay H; Savage DB; Temeloglu E; Uzum AK; Kadioglu P; Altay C; Ozen S; Demir L; Cavdar U; Akinci B
    Diabet Med; 2016 Oct; 33(10):1445-50. PubMed ID: 26756202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics, Phenotype of Lipodystrophy and a Genetic Analysis of Six Diabetic Japanese Women with Familial Partial Lipodystrophy in a Diabetic Outpatient Clinic.
    Iwanishi M; Ito-Kobayashi J; Washiyama M; Kusakabe T; Ebihara K
    Intern Med; 2018 Aug; 57(16):2301-2313. PubMed ID: 29607946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons from human mutations in PPARgamma.
    Hegele RA
    Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance.
    Boschmann M; Engeli S; Moro C; Luedtke A; Adams F; Gorzelniak K; Rahn G; Mähler A; Dobberstein K; Krüger A; Schmidt S; Spuler S; Luft FC; Smith SR; Schmidt HH; Jordan J
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1634-43. PubMed ID: 20130076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
    Lüdtke A; Buettner J; Schmidt HH; Worman HJ
    J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3.
    Miehle K; Porrmann J; Mitter D; Stumvoll M; Glaser C; Fasshauer M; Hoffmann K
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):141-8. PubMed ID: 26119484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.
    Sekizkardes H; Cochran E; Malandrino N; Garg A; Brown RJ
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3068-3076. PubMed ID: 31194872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy.
    Araújo-Vilar D; Lado-Abeal J; Palos-Paz F; Lattanzi G; Bandín MA; Bellido D; Domínguez-Gerpe L; Calvo C; Pérez O; Ramazanova A; Martínez-Sánchez N; Victoria B; Costa-Freitas AT
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):61-8. PubMed ID: 18031308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Primary lipodystrophies].
    Capeau J; Magré J; Lascols O; Caron M; Béréziat V; Vigouroux C
    Ann Endocrinol (Paris); 2007 Feb; 68(1):10-20. PubMed ID: 17320032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty acid metabolism in patients with PPARgamma mutations.
    Tan GD; Savage DB; Fielding BA; Collins J; Hodson L; Humphreys SM; O'Rahilly S; Chatterjee K; Frayn KN; Karpe F
    J Clin Endocrinol Metab; 2008 Nov; 93(11):4462-70. PubMed ID: 18713822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial partial lipodystrophy associated with the heterozygous LMNA mutation 1445G>A (Arg482Gln) in a Polish family.
    Drac H; Madej-Pilarczyk A; Gospodarczyk-Szot K; Gaweł M; Kwieciński H; Hausmanowa-Petrusewicz I
    Neurol Neurochir Pol; 2010; 44(3):291-6. PubMed ID: 20625965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dunnigan-type familial partial lipodystrophy associated with the heterozygous R482W mutation in LMNA gene - case study of three women from one family.
    Nabrdalik K; Strózik A; Minkina-Pędras M; Jarosz-Chobot P; Młynarski W; Grzeszczak W; Gumprecht J
    Endokrynol Pol; 2013; 64(4):306-11. PubMed ID: 24002959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LMNA gene mutation search in Polish patients: new features of the heterozygous Arg482Gln mutation phenotype.
    Klupa T; Szopa M; Skupien J; Wojtyczek K; Cyganek K; Kowalska I; Malecki MT
    Endocrine; 2009 Dec; 36(3):518-23. PubMed ID: 19859838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome.
    Maraldi NM; Capanni C; Mattioli E; Columbaro M; Squarzoni S; Parnaik WK; Wehnert M; Lattanzi G
    Acta Biomed; 2007; 78 Suppl 1():207-15. PubMed ID: 17465333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.